Prediction of outcome of early ER+ breast cancer is improved using a biomarker panel, which includes Ki-67 and p53
2011

Improving Breast Cancer Prognosis with Biomarkers

Sample size: 498 publication 10 minutes Evidence: high

Author Information

Author(s): Millar E K A, Graham P H, McNeil C M, Browne L, O'Toole S A, Boulghourjian A, Kearsley J H, Papadatos G, Delaney G, Fox C, Nasser E, Capp A, Sutherland R L

Primary Institution: Garvan Institute of Medical Research

Hypothesis

Does the assessment of Ki67 and p53 improve the prognostication of oestrogen receptor-positive breast cancer after breast-conserving therapy?

Conclusion

The prognostic evaluation of ER+ breast cancer is improved using a marker panel that includes Ki-67 and p53.

Supporting Evidence

  • 73 patients previously classified as luminal A were re-classified as luminal B, indicating a significant change in prognosis.
  • Multivariate analysis showed that the luminal B signature independently predicted locoregional recurrence, distant metastasis-free survival, and breast cancer-specific survival.
  • The study demonstrated that the updated biomarker panel provided superior predictive power compared to traditional classifications.

Takeaway

This study found that using certain markers can help doctors better predict how likely it is for breast cancer to come back after treatment.

Methodology

The study assessed 498 patients using immunohistochemical analysis of Ki67 and p53 to classify ER+ tumors and predict outcomes.

Potential Biases

Potential bias in classification due to subjective interpretation of histological grade.

Limitations

Recurrence rates may be overestimated for LB tumors due to the lack of Herceptin treatment, and the cut points for Ki67 positivity varied between cohorts.

Participant Demographics

Median age was 54 years; 40% of tumors were >20 mm, 45% were grade 3, and 43% were lymph node positive.

Statistical Information

P-Value

P=0.003 for LRR, P=0.002 for DMFS, P=0.002 for BCSS

Confidence Interval

95% CI 1.555–8.340 for LRR, 95% CI 1.501–6.087 for DMFS, 95% CI 1.629–8.031 for BCSS

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1038/bjc.2011.228

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication